you are here: HomeNewsIndia

COVID-19 antibody seroprevalence down at 25% in Delhi: Survey report in Delhi HC

The report was placed before a bench of Justices Hima Kohli and Subramonium Prasad during the hearing on a PIL seeking increase in the COVID-19 testing numbers in the national capital and getting speedy results.

September 30, 2020 / 06:00 PM IST
Delhi High Court

Delhi High Court

Seroprevalence of antibodies to COVID-19 reduced to 25 percent in September from nearly 29 percent last month among people in the national capital, the Delhi High Court was informed on Wednesday.

These are the findings of the third round of sero surveillance carried out by the AAP government in the national capital between September 1 to September 7.

The report was placed before a bench of Justices Hima Kohli and Subramonium Prasad during the hearing on a PIL seeking increase in the COVID-19 testing numbers in the national capital and getting speedy results.

The report, filed through Delhi government additional standing counsel Satyakam, indicated that there was a reduction in the "antibody seroprevalence" from 28.7 percent in August to 25.1 percent in September.

It also showed that there was a significant decrease in seroprevalence in north east, north and central districts of Delhi, while there was a slight increase in south, east, west and north west districts.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

The seroprevalence was more in females during all the rounds of the survey and it was the least in the 18-49 years age group, as compared to age groups of less than 18 years and more than 50 years, it said.

"Seroprevalence was increased in participants belonging to the low socio-economic status and those living in unplanned colonies,” the report said and added that this was probably due to difficulties in maintaining social distancing and hygiene measures amongst people of these categories.

The Delhi government surveyed 17,409 people across the national capital.

The report stated that asymptomatic infections were manifested in most cases during all the sero survey rounds and diabetes mellitus was observed to be a risk factor for subclinical infection.

The sero survey also found that nearly one-third of the participants with a past history of COVID-19 infection, "did not have detectable IgG antibodies”.

"However, there is evidence that antibodies to COVID-19 may deplete over time,” it added.

The surveyors have recommended that there is a need to space the sero survey rounds and future surveillance should focus more on "ensuring representativeness of the sample in terms of settlement type and socio-economic status”.

The Delhi government told the bench that it will inform the court on the next date of hearing on October 7 as to when it will conduct the next round of sero survey.

Follow our full coverage of the coronavirus pandemic here.
PTI
first published: Sep 30, 2020 07:58 pm

stay updated

Get Daily News on your Browser
Sections